Phase III Clinical Trial of NPB-01 in Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids.

NCT01696500 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Stevens-Johnson Syndrome
Toxic Epidermal Necrolysis

Interventions

DRUG: Intravenous immunoglobulin

Sponsor

Nihon Pharmaceutical Co., Ltd